Peptide News Digest

#Maveropepimut-S

2 stories

Clinical Trials · View digest

BioVaxys MVP-S Survivin Peptide Vaccine Reaches ASCO 2026 With Positive PESCO Phase 1b/2 Data in Recurrent Ovarian Cancer

BioVaxys presented results from the investigator-initiated PESCO trial of maveropepimut-S (MVP-S) combined with pembrolizumab and low-dose cyclophosphamide in recurrent epithelial ovarian cancer. MVP-S is a DPX-based vaccine built from five survivin-derived peptides plus a T-helper peptide and an innate immune stimulant, designed to drive a cytotoxic T-cell response against survivin, an antigen highly expressed in ovarian tumors but nearly absent in normal tissue.

Clinical Trials · View digest

BioVaxys MVP-S Survivin Peptide Vaccine PESCO Phase 1B/2 Trial Accepted at ASCO 2026 in Recurrent Ovarian Cancer

BioVaxys announced April 27 that the abstract from the investigator-initiated PESCO trial — an open-label, non-randomized Phase 1B/2 study evaluating the company's MVP-S (maveropepimut-S) DPX-formulated peptide vaccine in combination with pembrolizumab and cyclophosphamide in recurrent epithelial ovarian cancer — has been accepted for presentation at the 2026 ASCO Annual Meeting in Chicago (May 29–June 6). MVP-S is a five-peptide survivin-targeted formulation that pairs the peptides with a T-helper sequence and an innate-immune stimulant; the program tests whether the cytotoxic T-cell response can be combined effectively with checkpoint blockade in platinum-resistant disease.